Brief: Epigenomics: New Clinical Data On Epi ProColon Blood Test For Colorectal Cancer Screening
17/06/2019 13:05
June 17 (Reuters) - EPIGENOMICS AG ECXn.DE :
* NEW CLINICAL DATA SUPPORT THE UTILITY OF EPI PROCOLON(R)
BLOOD
TEST FOR COLORECTAL CANCER (CRC) SCREENING IN PATIENTS WITH
LYNCH SYNDROME (LS), THE MOST COMMON HEREDITARY CRC SYNDROME
Source text for Eikon: ID:nEQ2ljw9ca
Further company coverage: ECXn.DE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns